Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2015 | Overview of a promising new study of venetoclax in patients with CLL

Jacqueline Barrientos • 6 Jan 2016
ASH 2015
Chronic Lymphocytic Leukemia Venetoclax

Jacqueline Barrientos, MD, from the North Shore-Long Island Jewish Health System in New York, discusses a promising new study of the anti-apopotopic (Bcl-2 inhibitor) venetoclax in patients with CLL. Early data suggest that this may achieve minimum residual disease (MRD) negativity with a low risk of side effects.

More from Jacqueline Barrientos

2:18
Advancements within the CLL treatment landscape
Jacqueline Barrientos • 13 Dec 2021
1:12
Novel treatment strategies for Richter’s transformation
Jacqueline Barrientos • 13 Dec 2021
2:37
Customizing CLL care with BTK Inhibitors
Jacqueline Barrientos • 13 Dec 2021
2:21
CAPTIVATE: Ibrutinib and venetoclax in CLL
Jacqueline Barrientos • 13 Dec 2021

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
The content of VJHemOnc is intended for healthcare professionals